Mexico Biosurgery Market Overview, 2031

Key Insights
• The Mexico biosurgery market is distinguished by its rapid growth trajectory, driven by unprecedented government investment in healthcare infrastructure, a historic expansion of surgical volumes, and increasing adoption of advanced medical technologies. With the Mexican Institute of Social Security (IMSS) alone performing 1.78 million surgeries in 2025 a 30% increase over 2024 the demand for biosurgical products is accelerating at an exceptional pace. The market is shaped by major healthcare reforms, including the ""2-30-100"" strategy targeting 2 million surgeries, 30 million specialty consultations, and 100 million family medicine consultations annually. Mexico's biosurgery market benefits from a growing private healthcare sector, rising medical tourism, and increasing adoption of minimally invasive surgical techniques, positioning it as the fastest-growing country in North America with a projected CAGR of 6.42% from 2026 to 2031.
• The Mexican market accounts for an estimated 3.95% of the North American biosurgery market. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.
• Mexico is experiencing a historic healthcare infrastructure expansion, with 31 new hospitals, 12 clinics, and 256 operating rooms being activated in 2025 under a MXN 90 billion investment program. This expansion, combined with the government's ""2-30-100"" strategy, is fundamentally transforming surgical capacity and driving biosurgery market growth.
• Bone-graft substitutes constitute a major market pillar, supported by the high volume of orthopedic and trauma surgeries. Traumatology and Orthopedics was among the fastest-growing medical specialties in IMSS during 2025, reflecting the increasing burden of musculoskeletal conditions and road traffic injuries. Hemostatic agents represent the largest product category within the Mexican biosurgery market, driven by their essential application across all surgical specialties. With IMSS performing 1.78 million surgeries in 2025 a 30% increase over 2024 demand for advanced bleeding control solutions has intensified significantly.
• The regulatory environment, centered on COFEPRIS (Federal Commission for Protection against Sanitary Risks), is evolving to facilitate faster market access. In September 2025, COFEPRIS launched an Abbreviated Regulatory Pathway that accepts existing FDA, Health Canada, and other IMDRF-recognized approvals with a target review window of 30 days.
Market Outlook
• According to the research report, “Mexico Biosurgery market Outlook, 2031,” published by Bonafide Research, the Mexico Biosurgery market is anticipated to grow at more than 6.42% CAGR from 2026 to 2031.
• Mexico's healthcare system is undergoing a historic transformation. The federal government has invested over MXN 90 billion in healthcare infrastructure, with 31 new hospitals, 12 clinics, and 256 operating rooms being activated in 2025. An additional 20 hospitals are planned for construction between 2025 and 2027. This infrastructure expansion is fundamentally increasing surgical capacity across the public health system.
• The ""2-30-100"" strategy, launched by President Claudia Sheinbaum's administration, targets 2 million surgeries, 30 million specialty consultations, and 100 million family medicine consultations annually. In 2025, IMSS achieved 1.78 million surgeries a 30% increase over 2024 and a 60% increase over 2018 levels. This surgical volume expansion directly drives demand for biosurgical products across all categories.
• The aging Mexican population represents a significant long-term demand driver. With healthcare expenditure per capita reaching approximately USD 876 in 2025, the expanding elderly demographic will drive increased demand for orthopedic, cardiovascular, and other surgical interventions requiring biosurgical products.
• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. The adoption of robotic-assisted surgery is accelerating in Mexico, with the Edomex public hospital system acquiring its first Da Vinci Surgical System and performing 19 successful robotic surgeries in 2025. Robotic knee replacement surgery has been introduced at IMSS UMAE facilities.
Market Dynamics
Driver: Historic Expansion of Surgical Volumes and Healthcare Infrastructure
The Mexican biosurgery market is experiencing unprecedented growth driven by the most significant healthcare infrastructure expansion in the country's modern history. In 2025, the IMSS performed 1.78 million surgeries a 30% increase over 2024 and a 60% increase over 2018 levels. This represents 670,000 additional surgeries compared to 2018. The government has invested over MXN 90 billion in healthcare infrastructure, activating 31 new hospitals and 256 operating rooms in 2025, with 20 additional hospitals planned for construction through 2027. The ""2-30-100"" strategy targets 2 million surgeries annually, creating sustained demand for biosurgical products across all categories. These investments directly translate into increased utilization of hemostatic agents, surgical sealants, bone-graft substitutes, and other biosurgical products.

Challenge: Healthcare Spending Constraints and Infrastructure Gaps
Despite significant government investment, Mexico's healthcare system faces persistent challenges that limit the full potential of the biosurgery market. Healthcare expenditure in Mexico stands at approximately 5.71% of GDP, significantly below the OECD average of 9.3%. Per capita health spending of approximately USD 876 ranks among the lowest in Latin America relative to the size of the economy. The public health budget for 2025 (MXN 881.08 billion) was 12.2% lower than the amount approved for 2024. Additionally, infrastructure gaps persist, with some hospitals unable to operate due to lack of surgical personnel or equipment. These financial and operational constraints create pricing pressure on biosurgical products and may limit adoption of premium-priced advanced biologics in the public sector.

Trend: Accelerating Adoption of Minimally Invasive and Robotic-Assisted Surgery
The Mexican biosurgery market is experiencing a significant trend toward minimally invasive and robotic-assisted surgical techniques. The Edomex public hospital system acquired its first Da Vinci Surgical System in 2025, performing 19 successful robotic surgeries. IMSS has introduced robotic knee replacement surgery at its UMAE facilities, with the service performing approximately 2,400 knee arthroplasties and 1,900 hip arthroplasties annually. The robotic surgery program is expected to increase surgical capacity by up to 20% annually. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for robotic and minimally invasive procedures, particularly surgical sealants and adhesives optimized for laparoscopic delivery and hemostatic agents compatible with robotic instrumentation.
Policies
• COFEPRIS (Federal Commission for Protection against Sanitary Risk) regulates medical devices in Mexico under the Health General Law. Medical devices are classified based on risk level, with surgical materials and healing products recognized as medical devices subject to regulatory oversight.
• COFEPRIS launched an Abbreviated Regulatory Pathway in September 2025 that accepts existing FDA, Health Canada, and other IMDRF-recognized approvals with a target review window of 30 working days. This pathway significantly accelerates market access for biosurgical products already approved in reference markets.
• Medical device registration through COFEPRIS requires submission of sanitary registration applications, with Class I low-risk devices typically exempt from registration while Class II and III devices require full review. Registration certificates are valid for five years and can be renewed.
• NOM-137-SSA1-2008 establishes labeling requirements for medical devices in Mexico, including biosurgical products. All devices must comply with these labeling standards to obtain and maintain COFEPRIS registration.
• The ""2-30-100"" strategy represents the federal government's commitment to expanding surgical capacity, targeting 2 million surgeries, 30 million specialty consultations, and 100 million family medicine consultations annually. This policy directly drives biosurgical product demand.
• MXN 90 billion healthcare infrastructure investment (October 2024–December 2025) is activating 31 hospitals, 12 clinics, and 256 operating rooms, with 20 additional hospitals planned through 2027. This expansion fundamentally increases surgical capacity and biosurgery market potential.
Segment Analysis
Mexico Biosurgery Market By Product • Hemostatic Agents represent the major product category within the Mexican biosurgery market, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. With IMSS performing 1.78 million surgeries in 2025, demand for hemostatic products has grown substantially. The Mexico hemostats market was valued at approximately USD 160 million in 2025.
• Bone-Graft Substitutes constitute a major market segment, supported by the high volume of orthopedic and trauma surgeries. Traumatology and Orthopedics was among the fastest-growing medical specialties in IMSS during 2025. The Mexico bone grafts and substitutes market generated approximately USD 42.7 million in revenue in 2025. Demand is driven by spinal fusion procedures, trauma cases, and joint replacement surgeries.
• Surgical Sealants and Adhesives represent a dynamic and growing product category, driven by increasing adoption of minimally invasive surgical techniques and the expanding volume of surgical procedures. These products are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The Mexico hemostasis and tissue sealing agents market continues to experience steady growth driven by increasing surgical procedures and rising prevalence of chronic diseases.
• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines. The rising prevalence of obesity and increasing bariatric surgery volumes in Mexico drive demand for these products.
• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and other soft-tissue procedures.
• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries, supported by ongoing product innovation and clinical evidence.

Mexico Biosurgery Market By Application • Orthopedic Surgery is the largest application area for biosurgical products in Mexico, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures. IMSS reported Traumatology and Orthopedics among the fastest-growing specialties in 2025. IMSS UMAE facilities perform approximately 2,400 knee arthroplasties and 1,900 hip arthroplasties annually.
• General Surgery encompasses abdominal, gastrointestinal, and soft-tissue procedures including bariatric surgery, colorectal surgery, and hernia repair. IMSS reported General Surgery among the fastest-growing specialties in 2025.
• Cardiovascular Surgery represents a high-value application area for biosurgical products, including vascular sealants and hemostatic agents. Cardiology was identified among the growing medical specialties in IMSS during 2025.
• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks. Mexico is developing minimally invasive neurosurgery capabilities.
• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery and the rising burden of lung and esophageal cancers.
• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues following injury, disease, or surgery.
• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, and adhesion prevention.
• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with the Hugo™ robotic-assisted surgery system licensed for urologic laparoscopic procedures.

Mexico Biosurgery Market By Source/Origin • Biologic products derived from human, animal, or microbial sources have traditionally been preferred in the Mexican market due to their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts.
• Synthetic and Semi-Synthetic products are gaining share in Mexico due to cost-effectiveness, consistent quality, and lower immunogenicity risks. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The price sensitivity of the Mexican public healthcare system favors synthetic alternatives for certain applications.



Mexico Biosurgery Market By End-User • Hospitals remain the largest end-user segment for biosurgical products in Mexico, accounting for the majority of revenue. Public hospitals under IMSS, ISSSTE, and IMSS-Bienestar perform the vast majority of surgical procedures in Mexico. Private hospitals serve the growing medical tourism and private healthcare segments.
• Ambulatory Surgical Centers (ASCs) represent a growing end-user segment in Mexico. The National Rehabilitation Institute has expanded its ambulatory surgery program to include five specialties, including Traumatology, Pediatric Orthopedics, Spine Surgery, Ophthalmology, and Bone Tumors. Saturday ambulatory surgeries have been consolidated to reduce wait times.
• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products. The expansion of outpatient care networks in urban and semi-urban areas supports clinic-based procedure growth.


Mexico Biosurgery Market Economics

• Mexico’s biosurgery market operates through a dual healthcare system, with public institutions such as IMSS, ISSSTE, and IMSS-Bienestar serving most patients and a growing private sector serving higher-income patients and medical tourists. Healthcare spending remains relatively low at approximately 5.71% of GDP, creating strong pricing pressure, particularly in public procurement. Public-sector products are primarily purchased through centralized tenders, while private hospitals use direct agreements. Despite these pressures, Mexico’s proximity to the U.S., skilled workforce, USMCA participation, and expanding medical-device manufacturing base support commercial investment and supply-chain development.
• Market Outlook by Infrastructure, Investment and Industry Development: Mexico is significantly expanding healthcare and surgical capacity. In 2025, more than MXN 90 billion was invested to activate 31 hospitals, 12 clinics, and 256 operating rooms, with additional hospitals planned through 2027. IMSS reported approximately 1.78 million surgeries in 2025 and is targeting 2 million annually, while additional specialists and workforce training are being added to address capacity constraints. Investment in robotic and minimally invasive surgery is also increasing, including Da Vinci and Hugo™ systems and robotic knee-replacement procedures, creating opportunities for advanced biosurgical products.
• Long-Term Growth Outlook: The Mexican biosurgery market is positioned for sustained growth, supported by rising surgical volumes, healthcare infrastructure expansion, technology adoption, and increasing investment. COFEPRIS regulatory modernization, including an abbreviated pathway recognizing certain FDA, Health Canada, and IMDRF approvals, can accelerate access to innovative medical devices. However, manufacturers must manage public-sector pricing pressure, centralized procurement, regulatory requirements, and differences between public and private healthcare. Overall, expanding surgical capacity and adoption of advanced technologies should continue to drive demand for biosurgical products across Mexico.

Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Biosurgery Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Bone-Graft Substitutes
• Hemostatic Agents
• Surgical Sealants & Adhesives
• Adhesion Barriers
• Soft-Tissue Attachments
• Staple-Line Reinforcement

By Application:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Urological Surgery
• Other surgeries (Thoracic surgeries & more)

By Source/Origin
• Biologic
• Synthetic / Semi-synthetic

By End-user:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others"